"The LIGHTHOUSE Study is a global Phase 3 trial expected to enroll approximately 400 PD participants with LRRK2 mutations. The LUMA Study is a global Phase 2b trial expected to enroll approximately 640 participants with PD who do not carry a LRRK2 mutation and is designed to potentially support registration of BIIB122"
Denali Therapeutics announced, LIGHTHOUSE... - Cure Parkinson's
Denali Therapeutics announced, LIGHTHOUSE, Phase 3
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of their...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
l-for-european-union-clinical-trial-sites-for-the-phase-3-study-of-buntanetap-for-the-treatment-of-p
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
the point of unblinding the data for the PD Phase III study, we discovered an unexpected issue: too...
Anyone participating in the Buntanetap Phase 3 trial?
initial feedback. I'm considering participating. Full info here:...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
1# endpoint=UPDRS II+III OFF
https://twitter.com/ScienceofPD/status/1545320232666923009
Related Posts
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
Phase 3 Positive Topline Results for Tavapadon 
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.- First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
-
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
